Abstract: This invention will allow men suffering from full and periodic erectile dysfunction to achieve, or at least assist in the process of achieving a firm and lasting erection. And, for all men, this device will be able to measure blood-flow to the penis, as well as increase sexual pleasure through micro-electronic stimulation to the penis (induce erection). Blood-flow data captured from devices' internal sensors will be processed by software and presented to users via a smart-phone app to provide useful, actionable, and customizable tasks to improve penile and overall sexual performance, health, and wellness.

Abstract: This invention will allow men suffering from full and periodic erectile dysfunction to achieve, or at least assist in the process of achieving a firm and lasting erection. And, for all men, this device will be able to measure blood-flow to the penis, as well as increase sexual pleasure through micro-electronic stimulation to the penis (induce erection). Blood-flow data captured from devices' internal sensors will be processed by software and presented to users via a smart-phone app to provide useful, actionable, and customizable tasks to improve penile and overall sexual performance, health, and wellness.

Abstract: The present invention provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease: wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, —OCH3, C1-C3 alkyl; R3 is H, —CH3, or —OCH3; and R4 is H or F; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides compounds of Formula I useful as BACE inhibitors in the treatment of e.g. Alzheimer's disease: wherein A is selected from the group consisting of; of; R1 is H or F; R2 is H, —OCH3, C1-C3 alkyl; R3 is H, —CH3, or —OCH3; and R4 is H or F; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides single nucleotide polymorphisms (SNPs) associated with clinical responsiveness of rheumatoid arthritis patients to treatment with an interleukin-6 receptor antibody such as tocilizumab, and methods of using such SNPs for predicting clinical response to treatment with the antibody.

Abstract: Compounds of the formula I or a pharmaceutically acceptable salt thereof: processes for their preparation, pharmaceutical compositions which contain them and their uses in therapy.

Abstract: Described herein are compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O; Alk is (C1-4) alkylene or hydroxy substituted (C1-4) alkylene; X is oxygen or sulfur; R1 is hydrogen, (C1-6) fluroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, or —CN; R2 is H, halogen, (C1-6) fluoroalkyl, (C1-6) cycloalkyl, OR4, SR4, NO2, CN, COR4, C(O)OR4, CONR5R6, NR5R6, SO2NR5R6, NR5COR4, NR5SO2R4, optionally substituted aromatic, or (C1-6) alkyl, wherein (C1-6) alkyl is unsubstituted or substituted with a hydroxy group; R3 is hydrogen (C1-6) fluoroalkyl, (C2-6) alkenyl, Ar, (C1-4)alkyl-Ar, or (C1-4) alkyl wherein (C1-4) alkyly is unsubstituted or substituted with a phenyl; R4 is hydrogen, (C1-6) alkyl, (C1-6) fluoroalkyl, or optionally substituted aromatic; R5 and R6 are independently hydrogen, (C1-6) alkyl, or optionally

Abstract: Sequence #115, a G protein-coupled receptor, has been identified as a target for identifying weight modulating compounds. Compounds that modulate sequence #115 may be useful for the treatment of obesity and cachexia. Cell-based and cell-free assays are described to identify compounds which bind to and/or activate or inhibit the activity of sequence #115.

Abstract: The MINOR and TR3 genes are disclosed to be insulin responsive genes differentially expressed as a function of insulin resistance and Type 2 Diabetes in humans and a variety of well characterized animal models. The present disclosure shows that MINOR and TR3 have a functional role in insulin resistance. Therefore, MINOR and TR3 are attractive and novel therapeutic targets for combating insulin resistance and/or disease states and conditions characterized by insulin resistance. Correlation of insulin resistance and disease states and conditions characterized by insulin resistance, including Type II diabetes, with MINOR and TR3 gene expression are also disclosed. Methods of diagnosis, treatment and prevention are likewise disclosed for the treatment and/or prevention of insulin resistance and disease states or conditions characterized by insulin resistance.

Abstract: The present invention relates to a nucleic acid sequence linked to Alström syndrome, variants of that nucleic acid sequence, the protein produced by that nucleic acid sequence and screening methods for testing individuals to determine if they are carriers of Alström syndrome.

Abstract: The present invention provides polypeptides which are correlated with pre-diabetes, diabetes or susceptibility to diabetes which can be used as markers for diagnosis of pre-diabetes, diabetes or a susceptibility or predisposition to develop diabetes. The invention also provides methods for the diagnosis of pre-diabetes, diabetes and/or the susceptibility to diabetes by obtaining a biological sample and detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Screening methods relating to agonists and antagonists of the specific polypeptides disclosed herein are provided. Antibodies may also be raised against these polypeptide markers for the detection and/or treatment of diabetes. Proteins, protein fragments or peptides can be used for the treatment of diabetes or pre-diabetes.

Abstract: Compounds of formula (I) are matrix metalloproteinase inhibitors wherein X represents a carboxylic acid group —COOH, or a hydroxamic acid group —CONHOH;R2 represents a radical of formula (II): R3—(ALK)m—(Q)p—(ALK)n—, and W represents a cyclic amino radical of formula (IIIA) or (IIIB): 1

Abstract: Compounds of formula (I) are matrix metalloprotemase inhibitors wherein X represents a carboxylic acid group —COOH, or a hydroxamic acid group —CONHOH;R2 represents a radical of formula (II): R3—(ALK)m—(Q)p—(ALK)n.

Abstract: A compound of formula (I) wherein X is —COOH or —CONHOH Y is a group of formula (ID) or (IE) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.

Abstract: A compound of formula (I) wherein X is a —CONHOH group and the R groups are defined in the claims. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation and inhibitors of the release of tumour necrosis factor from cells.

Abstract: The present invention relates to therapeutically active hydroxamic acid, N-formyl-N-hydroxyamino and carboxylic acid derivatives, their preparation, and pharmaceutical compositions containing them. These compounds are useful in the inhibition of metalloproteases, such as stromelysin, gelatinase, matrilysin, and collagenase. These compounds are useful in the treatment of mammals having disease-states alleviated by the inhibition of such matrix metalloproteases.

Abstract: A compound of formula (I) useful as metalloproteinase inhibitors.